Last updated: February 13, 2026
What is the drug associated with NDC 42291-0963?
The National Drug Code (NDC) 42291-0963 corresponds to Zarxio (filgrastim), a biosimilar used to stimulate white blood cell production in patients with neutropenia resulting from chemotherapy, bone marrow transplant, or other conditions. It is manufactured by Sandoz, a Novartis division.
Market Overview: Zarxio's market position and demand
Market Size:
The global granulocyte colony-stimulating factor (G-CSF) market, encompassing filgrastim products, was valued at approximately $4 billion in 2022 (source: Grand View Research). Biosimilars like Zarxio account for increasing market share, driven by cost pressures and patent expirations.
Key Competitors:
- Neupogen (original branded filgrastim, marketed by Amgen)
- Other biosimilars, such as Sandoz’s Zarxio (42291-0963), Biocon’s Aleplasmin, and others entering the space.
U.S. Market Dynamics:
- Patents on innovator products like Neupogen expired around 2015, opening the biosimilar market.
- FDA-approved biosimilars for filgrastim include Zarxio and others, intensifying competition.
- Payer preference shifts toward biosimilars for in-patient and outpatient chemotherapy protocols.
Driving Factors:
- Cost reductions of biosimilars versus branded products (cost savings estimated at up to 30-50%).
- Physician and hospital adoption driven by safety and efficacy equivalence.
Market Growth Rate:
The biosimilar segment for G-CSFs projected compound annual growth rate (CAGR) of 13% from 2022-2027 (source: MarketsandMarkets). The overall filgrastim market is expected to reach $6 billion by 2027.
Pricing Trends and Projections
Current Price Benchmarks:
- The average wholesale price (AWP) of Zarxio in the U.S. ranges from approximately $800 to $1,200 per 300 mcg dose.
- Injectable G-CSF cost per patient treatment varies based on dosage, typically around 3 to 6 vials per cycle, costing $2,400 to $7,200 per cycle.
Pricing Trajectory (Next 3-5 Years):
- Biosimilar pricing is generally lower than the innovator drugs.
- Price erosion anticipated to be 10-20% annually as biosimilar uptake increases.
- Increasing competition from additional biosimilars could push prices below $700 per 300 mcg dose in the U.S. by 2027.
Key Market Factors Influencing Price:
- Payer negotiations and formularies favoring lower-cost biosimilars.
- Policy and incentives encouraging biosimilar use, including CMS initiatives.
- Manufacturer strategies including discounts, rebates, and value-based contracting.
Regulatory Environment and its impact
The FDA approved Zarxio in 2015 as the first biosimilar in the U.S. (reference: FDA approval notice).
The regulatory pathway has streamlined biosimilar approvals but remains complex concerning interchangeability and substitution policies at state levels.
Impairment Factors:
- Patent litigation delays.
- Variability in state substitution laws affecting market penetration.
Market Risks and Opportunities
Risks:
- Slow adoption due to physician and patient preferences for branded products.
- Potential regulatory or legislative barriers complicating substitution policies.
- Entry of additional biosimilars leading to price competition.
Opportunities:
- Incremental volume growth through expanding indications.
- Strategic partnerships with healthcare providers.
- Making use of value-based reimbursement models to incentivize biosimilar use.
Summary: Price Forecast for NDC 42291-0963 (Zarxio)
| Year |
Estimated Price Range (per 300 mcg vial) |
Market Share Outlook |
Key Influencing Factors |
| 2023 |
$800 - $1,200 |
30-40% |
Adoption rate. Price competition. |
| 2024 |
$700 - $1,000 |
40-50% |
Increased biosimilar penetration. |
| 2025 |
$700 - $900 |
50-60% |
Payer preferences. Price erosion. |
| 2026 |
$650 - $850 |
60-70% |
Expanded formulary coverage. |
| 2027 |
Below $700 |
70%+ |
Market saturation. Further pricing pressure. |
Key Takeaways
- Zarxio (filgrastim biosimilar) holds a significant share in the G-CSF market with expected steady growth.
- Price erosion is likely driven by patent expirations, increased biosimilar adoption, and competitive pressures, with prices potentially falling below $700 in the next 4 years.
- Market expansion depends on payer reimbursement policies and physician acceptance.
- Biosimilar regulation and policy shifts, such as interchangeability designations, could accelerate price declines.
FAQs
1. How does Zarxio compare to its innovator Neupogen in price?
Zarxio typically costs 30-50% less than Neupogen, depending on dosage and negotiations.
2. What are the main factors influencing biosimilar pricing?
Market competition, payer policies, regulatory environment, manufacturing costs, and adoption rates.
3. Will price reductions impact biosimilar profitability?
Yes. Reduced prices must be balanced with production costs and volume growth to sustain profitability.
4. How does regulatory approval affect biosimilar market entry?
Favorable FDA approvals and interchangeability designations can accelerate adoption and price declines.
5. What is the outlook for biosimilar market share in G-CSF?
Expected to surpass 70% in the U.S. within 5 years, driven by cost incentives and regulatory encouragement.
Citations
- Grand View Research. G-CSF Market Size, Share & Trends Analysis Report, 2022.
- MarketsandMarkets. Biosimilar Market Forecast, 2022-2027.
- FDA. Approval notices and biosimilar guidelines.
- Sandoz. Zarxio product information and pricing.
- IQVIA. Healthcare database and pricing reports.
[1] Grand View Research
[2] MarketsandMarkets
[3] FDA reports
[4] Sandoz official disclosures
[5] IQVIA data
